Back to Search
Start Over
Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.
- Source :
-
Expert opinion on biological therapy [Expert Opin Biol Ther] 2006 Apr; Vol. 6 (4), pp. 391-9. - Publication Year :
- 2006
-
Abstract
- Ranpirnase (Onconase) is a novel cytotoxic ribonuclease. In clinical development as a single agent in patients with malignant mesothelioma (MM), at 480 microg/m2 intravenously weekly, analysis of survival indicated prolonged periods of stable disease in Phase II trials and a potential survival benefit, compared with doxorubicin, in a small unpublished Phase III trial. In all clinical studies it has generally demonstrated a favourable safety profile except for easily controlled allergic reactions and dose modifications for renal impairment. Standard first-line treatment for MM has recently been established with an antifolate and cisplatin. At present, a Phase III trial of doxorubicin with or without ranpirnase is nearing completion in MM patients without prior chemotherapy or one prior chemotherapy regimen.
Details
- Language :
- English
- ISSN :
- 1744-7682
- Volume :
- 6
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Expert opinion on biological therapy
- Publication Type :
- Academic Journal
- Accession number :
- 16548765
- Full Text :
- https://doi.org/10.1517/14712598.6.4.391